Eli Lilly & Co. and China's Innovent Biologics agreed to co-develop at least three experimental cancer drugs--including one from Lilly's research labs and two from Innovent--in a deal that will see the Indianapolis-based company pay $56 million upfront.
Eli Lilly is betting up to $690 million that a drug from Korea's Hanmi Pharmaceutical can successfully treat an array of autoimmune diseases, licensing an early-stage candidate with ambitious plans for future trials.
Hutchison China MediTech, based in Hong Kong, expects to file for its first drug approval next year for what it said would be the first modern drug developed in China since artemisinin was developed in the 1970s to treat malaria.
Denovo Biopharma will conduct clinical trials in China for its exclusively licensed pomaglumetad methionil, a late-stage neuroscience drug licensed from Eli Lilly.
Phase II results of the first clinical trial of a tau aggregation inhibitor for Alzheimer's disease were published last month in the Journal of Alzheimer's Disease, with Singapore-based TauRx Pharmaceuticals saying it was an important milestone as it moves to report top line results from a Phase III study in 2016.
Eli Lilly's long-acting basal insulin peglispro is on the back burner now. Some analysts figure it's well on its way to being canned. But the news isn't quite as bad for Lilly as one might expect--nor quite as good for the drug peglispro was hoping to challenge, Sanofi's Lantus.
Everybody sees something different when they look at Eli Lilly, which has recently dropped out of the top 10 pharma group. A number of analysts, some with good reason to shine up to CEO John Lechleiter, see a company that has hit bottom and is on the comeback trail, with new drug approvals to help bolster Lechleiter's bullish forecasts.
Eli Lilly's already-delayed new insulin has run into another roadblock, as potentially harmful liver side effects have sent the company back to the clinic, putting off a potential regulatory filing by a year or more and leading a top analyst to eulogize the program.
Eli Lilly is extending its massive Phase III trial on a new cardio drug by 6 months in what the company says is a reaction to some recent developments in science.
One major news organization suggesting improper actions by members of your profession is bad enough; two is downright painful--and possibly unjustified. That's the message from Ted Cohn, president of the American Veterinary Medical Association, who has officially denounced what he calls a series of "attack" articles on veterinarians that allege their relationships with drug companies are unethical.